European Surveillance of Antimicrobial Consumption (ESAC): outpatient systemic antimycotic and antifungal use in Europe

• Published in: Journal of antimicrobial chemotherapy 2010-04, Vol.65 (4), p.769-774
• Main Authors: Adriaenssens, Niels, Coenen, Samuel, Muller, Arno, Vankerckhoven, Vanessa, Goossens, Herman
• Format: Article
• Language: English
• Subjects: Ambulatory Care; Antibiotics. Antiinfectious agents. Antiparasitic agents; antifungal agents; Antifungal Agents - therapeutic use; antimycotic use; Biological and medical sciences; Clinical medicine; drug consumption; Drug dosages; Drug therapy; Drug Utilization - statistics & numerical data; Drug Utilization - trends; Europe; Fungal infections; Fungi; Humans; Medical sciences; pharmacoepidemiology; Pharmacology. Drug treatments
• ISSN: 0305-7453; 1460-2091
• DOI: 10.1093/jac/dkq023

Objectives To assess the total outpatient systemic antimycotic and antifungal use in Europe, and to identify the antimycotic and antifungal substances most commonly used. Methods Within ESAC (www.esac.ua.ac.be), using the anatomical therapeutic chemical (ATC) and defined daily dose (DDD) classification, data on outpatient use of all 14 antimycotics (12) and antifungals (2) for systemic use (ATC J02 and D01B, respectively), aggregated at the level of the active substance, were collected for 2007. Use was expressed in DDD (WHO ATC/DDD, version 2008) per 1000 inhabitants per day (DID). Only countries for which data on both J02 and D01B use were available were included in the analysis. Results In 20 European countries (data for Cyprus and Estonia include hospital use), total outpatient systemic antimycotic and antifungal use varied by a factor of 6.7 between the country with the highest (3.03 DID in Belgium) and the country with the lowest (0.45 in Croatia) use. Terbinafine, ketoconazole, itraconazole and fluconazole represented >94% of the total outpatient antimycotic and antifungal use in all countries. Terbinafine use represented >50% of the total systemic antimycotic and antifungal use in 16 out of 20 countries (not in Croatia, Italy, Luxembourg and Bulgaria). Conclusions We present for the first time a standardized and validated data set of outpatient systemic antimycotic and antifungal use in Europe. Our study demonstrates a variation of antimycotic and antifungal use in Europe, as striking as that of antibiotic use. The ESAC data facilitate the auditing of antimycotic and antifungal prescribing, and the evaluation of the implementation of guidelines and public health policies to promote their judicious use.